• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Infect Dis . Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2

tetano

Editor, Senior Moderator
Clin Infect Dis


. 2022 Jun 24;ciac516.
doi: 10.1093/cid/ciac516. Online ahead of print.
Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020


Paulo Arnaldo[SUP] 1 [/SUP], Nédio Mabunda[SUP] 1 [/SUP], Peter Wesley Young[SUP] 2 [/SUP], Tiffany Tran[SUP] 2 [/SUP], Nádia Sitoe[SUP] 3 [/SUP], Imelda Chelene[SUP] 3 [/SUP], Armando Nhanombe[SUP] 4 [/SUP], Nália Isamael[SUP] 3 [/SUP], António Júnior[SUP] 5 [/SUP], Basílio Cubula[SUP] 6 [/SUP], Osvaldo Frederico Inlamea[SUP] 4 [/SUP], Eduardo Gudo[SUP] 4 [/SUP], Ilesh Vinodrai Jani[SUP] 4 [/SUP]



Affiliations

Abstract

Background: The extent of population exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was uncertain in many African countries during the onset of the pandemic.
Methods: We conducted a cross-sectional study and randomly selected and surveyed general population and occupational groups from July 6 to August 24, 2020, in three cities in Mozambique. Anti-SARS-CoV-2 specific immunoglobulins M and G antibodies were measured using a point-of-care rapid test. The prevalence was weighted for population (by age, sex, and city) and adjusted for test sensitivity and specificity.
Results: A total of 21,183 participants, including 11,143 from the general population and 10,040 from occupational groups, were included across all three cities. General population seropositivity (immunoglobulins M or G) prevalence was 3.0% (95% CI, 1.0-6.6) in Pemba, 2.1% (95% CI, 1.2-3.3) in Maputo City, and 0.9% (95% CI, 0.1-1.9) in Quelimane. The prevalence in occupational groups ranged from 2.8% (95% CI, 1.3-5.2) to 5.9% (95% CI, 4.3-8.0) in Pemba, 0.3% (95% CI, 0.0-2.2) to 4.0% (95% CI, 2.6-5.7) in Maputo City, 0.0% (95% CI, 0.0-0.7) to 6.6% (95% CI, 3.8-10.5) in Quelimane, and showed variations between the groups tested.
Conclusions: Exposure to SARS-CoV-2 was extensive during the first pandemic wave, and transmission may have been more intense among occupational groups. These data have been of utmost importance to inform public health intervention to control and respond to pandemic in Mozambique.
Previous presentations of findings: Results from this study were presented (in Portuguese) at the Mozambican Jornadas Nacionais de Saúde in Maputo, Mozambique on Aug 10, 2021 (abstract #108, title, Prevalência da exposição ao novo coronavírus em três cidades de Moçambique, Julho-Agosto de 2020).

Keywords: Mozambique; SARS-COV-2; Sero-prevalence; general population; higher-risk occupational groups.
 
Back
Top Bottom